Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
9,911
result(s) for
"Casein"
Sort by:
Autism : exploring the benefits of a gluten- and casein-free diet : a practical guide for families and professionals
\"Autism represents one of the biggest health challenges facing children today. Whilst experts around the globe strive to unravel and truly understand how autism develops and presents itself, relatively little is still known about the condition. Meanwhile, strong evidence has emerged that the diet in children on the autistic spectrum can have a significant role to play in the management of their symptoms. A growing body of research reveals that some challenging characteristics present in autism may be positively affected by the introduction of a gluten- and casein-free (GFCF) diet. Autism: Exploring the benefits of a gluten and casein free diet offers an easy-to-read alternative to sifting through the science. Written by experts in autism research, food, nutrition and dietetics, the book cuts through the science-speak to offer readers a no-nonsense overview of diet and autism together with a range of useful recipes and handy hints for making mealtimes fun for children with autism and related conditions\"-- Provided by publisher.
Book
Structural Analysis of Breast-Milk αsub.S1-Casein: An α-Helical Conformation Is Required for TLR4-Stimulation
Breast-milk α[sub.S1]-casein is a Toll-like receptor 4 (TLR4) agonist, whereas phosphorylated α[sub.S1]-casein does not bind TLR4. The objective of this study was to analyse the structural requirements for these effects. In silico analysis of α[sub.S1]-casein indicated high α-helical content with coiled-coil characteristics. This was confirmed by CD-spectroscopy, showing the α-helical conformation to be stable between pH 2 and 7.4. After in vitro phosphorylation, the α-helical content was significantly reduced, similar to what it was after incubation at 80 °C. This conformation showed no in vitro induction of IL-8 secretion via TLR4. A synthetic peptide corresponding to V[sup.77]-E[sup.92] of α[sub.S1]-casein induced an IL-8 secretion of 0.95 ng/mL via TLR4. Our results indicate that α[sub.S1]-casein appears in two distinct conformations, an α-helical TLR4-agonistic and a less α-helical TLR4 non-agonistic conformation induced by phosphorylation. This is to indicate that the immunomodulatory role of α[sub.S1]-casein, as described before, could be regulated by conformational changes induced by phosphorylation.
Journal Article
CK1α, CK1δ, and CK1ε are necrosome components which phosphorylate serine 227 of human RIPK3 to activate necroptosis
Necroptosis is a regulated necrotic cell death pathway, mediated by a supermolecular complex called the necrosome, which contains receptor-interacting protein kinase 1 and 3 (RIPK1, RIPK3) and mixed-lineage kinase domain-like protein (MLKL). Phosphorylation of human RIPK3 at serine 227 (S227) has been shown to be required for downstream MLKL binding and necroptosis progression. Tandem immunoprecipitation of RIPK3 reveals that casein kinase 1 (CK1) family proteins associate with the necrosome upon necroptosis induction, and this interaction depends on the kinase activity of RIPK3. In addition, CK1 proteins colocalize with RIPK3 puncta during necroptosis. Importantly, CK1 proteins directly phosphorylate RIPK3 at S227 in vitro and in vivo. Loss of CK1 proteins abolishes S227 phosphorylation and blocks necroptosis. Furthermore, a RIPK3 mutant with mutations in the CK1 recognition motif fails to be phosphorylated at S227, does not bind or phosphorylate MLKL, and is unable to activate necroptosis. These results strongly suggest that CK1 proteins are necrosome components which are responsible for RIPK3-S227 phosphorylation.
Journal Article
sup.2H and .sup.18O depletion of water close to organic surfaces
Hydrophilic surfaces influence the structure of water close to them and may thus affect the isotope composition of water. Such an effect should be relevant and detectable for materials with large surface areas and low water contents. The relationship between the volumetric solidâ¯:â¯water ratio and the isotopic fractionation between adsorbed water and unconfined water was investigated for the materials silage, hay, organic soil (litter), filter paper, cotton, casein and flour. Each of these materials was equilibrated via the gas phase with unconfined water of known isotopic composition to quantify the isotopic difference between adsorbed water and unconfined water. Across all materials, isotopic fractionation was significant (p0.05) and negative (on average -0.91â¯Â±â¯0.22â¯â° for .sup.18â16 O and -20.6â¯Â±â¯2.4â¯â° for .sup.2â1 H at an average solidâ¯:â¯water ratio of 0.9). The observed isotopic fractionation was not caused by solutes, volatiles or old water because the fractionation did not disappear for washed or oven-dried silage, the isotopic fractionation was also found in filter paper and cotton, and the fractionation was independent of the isotopic composition of the unconfined water. Isotopic fractionation became linearly more negative with increasing volumetric solidâ¯:â¯water ratio and even exceeded -4â¯â° for .sup.18â16 O and -44â¯â° for .sup.2â1 H. This fractionation behaviour could be modelled by assuming two water layers: a thin layer that is in direct contact and influenced by the surface of the solid and a second layer of varying thickness depending on the total moisture content that is in equilibrium with the surrounding vapour. When we applied the model to soil water under grassland, the soil water extracted from 7 and 20â¯cm depth was significantly closer to local meteoric water than without correction for the surface effect. This study has major implications for the interpretation of the isotopic composition of water extracted from organic matter, especially when the volumetric solidâ¯:â¯water ratio is larger than 0.5 or for processes occurring at the solid-water interface.
Journal Article
ACE inhibitory casein peptide lowers blood pressure and reshapes gut microbiota in a randomized double blind placebo controlled trial
Casein-derived peptides have been shown to reduce blood pressure in animal studies, but evidence from human trials remains limited. This study aimed to investigate the antihypertensive effect and possible mechanisms of a hydrolyzed casein peptide tablet containing GPFPIIV and FFVAPFPEVFGK (HCP-C7C12) in prehypertensive/hypertensive patients. In this double-blind, randomized, placebo-controlled clinical trial, 131 participants were recruited and randomly allocated to either the test product group (HCP) taking tablets containing HCP-C7C12 or the placebo group for an eight-week intervention. 114 participants finally completed the study. After the intervention, both the systolic blood pressure and diastolic blood pressure in the HCP group were significantly reduced (
P
< 0.01) by 9.41% and 9.53%, respectively. The antihypertensive mechanisms may involve (1) HCP-C7C12 acting as an angiotensin-converting enzyme inhibitor, reducing angiotensin II production, and (2) modulating amino acid abundance such as L-Arginine, L-valine, leucine, and phenylalanine, resulting in anti-inflammatory and antioxidant effects that improve endothelial function. Additionally, HCP-C7C12 exhibited prebiotic-like effects, activating the butyrate and propionate production pathway and increasing the abundance of gut microbes with anti-inflammatory potentials. Overall, long-term consumption of the HCP-C7C12 tablet could be advantageous for blood pressure control in prehypertensive or hypertensive individuals.
Journal Article
Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows’ milk
Background
Cows’ milk generally contains two types of β-casein, A1 and A2 types. Digestion of A1 type can yield the peptide β-casomorphin-7, which is implicated in adverse gastrointestinal effects of milk consumption, some of which resemble those in lactose intolerance. This study aimed to compare the effects of milk containing A1 β-casein with those of milk containing only A2 β-casein on inflammation, symptoms of post-dairy digestive discomfort (PD3), and cognitive processing in subjects with self-reported lactose intolerance.
Methods
Forty-five Han Chinese subjects participated in this double-blind, randomized, 2 × 2 crossover trial and consumed milk containing both β-casein types or milk containing only A2 β-casein. Each treatment period was 14 days with a 14-day washout period at baseline and between treatment periods. Outcomes included PD3, gastrointestinal function (measured by smart pill), Subtle Cognitive Impairment Test (SCIT), serum/fecal laboratory biomarkers, and adverse events.
Results
Compared with milk containing only A2 β-casein, the consumption of milk containing both β-casein types was associated with significantly greater PD3 symptoms; higher concentrations of inflammation-related biomarkers and β-casomorphin-7; longer gastrointestinal transit times and lower levels of short-chain fatty acids; and increased response time and error rate on the SCIT. Consumption of milk containing both β-casein types was associated with worsening of PD3 symptoms relative to baseline in lactose tolerant and lactose intolerant subjects. Consumption of milk containing only A2 β-casein did not aggravate PD3 symptoms relative to baseline (i.e., after washout of dairy products) in lactose tolerant and intolerant subjects.
Conclusions
Consumption of milk containing A1 β-casein was associated with increased gastrointestinal inflammation, worsening of PD3 symptoms, delayed transit, and decreased cognitive processing speed and accuracy. Because elimination of A1 β-casein attenuated these effects, some symptoms of lactose intolerance may stem from inflammation it triggers, and can be avoided by consuming milk containing only the A2 type of beta casein.
Trial registration
ClinicalTrials.gov/NCT02406469
Journal Article
Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes
Circadian pacemaking requires the orderly synthesis, posttranslational modification, and degradation of clock proteins. In mammals, mutations in casein kinase 1 (CK1) ε or δ can alter the circadian period, but the particular functions of the WT isoforms within the pacemaker remain unclear. We selectively targeted WT CK1ε and CK1δ using pharmacological inhibitors (PF-4800567 and PF-670462, respectively) alongside genetic knockout and knockdown to reveal that CK1 activity is essential to molecular pacemaking. Moreover, CK1δ is the principal regulator of the clock period: pharmacological inhibition of CK1δ, but not CK1ε, significantly lengthened circadian rhythms in locomotor activity in vivo and molecular oscillations in the suprachiasmatic nucleus (SCN) and peripheral tissue slices in vitro. Period lengthening mediated by CK1δ inhibition was accompanied by nuclear retention of PER2 protein both in vitro and in vivo. Furthermore, phase mapping of the molecular clockwork in vitro showed that PF-670462 treatment lengthened the period in a phase-specific manner, selectively extending the duration of PER2-mediated transcriptional feedback. These findings suggested that CK1δ inhibition might be effective in increasing the amplitude and synchronization of disrupted circadian oscillators. This was tested using arrhythmic SCN slices derived from Vipr2 −/− mice, in which PF-670462 treatment transiently restored robust circadian rhythms of PER2::Luc bioluminescence. Moreover, in mice rendered behaviorally arrhythmic by the Vipr2 −/− mutation or by constant light, daily treatment with PF-670462 elicited robust 24-h activity cycles that persisted throughout treatment. Accordingly, selective pharmacological targeting of the endogenous circadian regulator CK1δ offers an avenue for therapeutic modulation of perturbed circadian behavior.
Journal Article
Dietary Intervention in Infancy and Later Signs of Beta-Cell Autoimmunity
This study investigated whether feeding with a highly hydrolyzed milk formula would decrease the incidence of diabetes-associated autoantibodies in genetically susceptible children. The intervention appeared to have a long-lasting effect on markers of beta-cell autoimmunity.
Type 1 diabetes is defined by the loss of insulin-producing beta cells in the pancreatic islets in genetically susceptible persons. Overt diabetes is preceded by an asymptomatic period of highly variable duration
1
during which diabetes-associated autoantibodies appear in the peripheral circulation as markers of emerging beta-cell autoimmunity. Five disease-related autoantibodies predict the clinical manifestation of type 1 diabetes: islet-cell antibodies; insulin autoantibodies; and autoantibodies to glutamic acid decarboxylase (GAD), the tyrosine phosphatase-related insulinoma-associated 2 molecule (IA-2), and zinc transporter 8 (ZnT8).
2
,
3
Positivity for two or more antibodies signals a risk of 50 to 100% for the development of type . . .
Journal Article
Computational screening of natural inhibitors against Plasmodium falciparum kinases: Toward novel antimalarial therapies
An important worldwide problem is the resistance of Plasmodium falciparum to practically all antimalarial medications. Therefore, new treatment approaches are urgently needed. The development of antimalarial medications frequently involves two important therapeutic targets: casein kinase 2 (CK2) and cGMP-dependent protein kinase (PKG). To identify naturally occurring chemicals that could be used as antimalarial medications to combat multidrug-resistant P. falciparum , we used a multi-targeted in silico strategy in this study. The top 20 compounds, including the reference drug RY-1–65, were selected after pharmacophore-based virtual screening of naturally produced compounds. These compounds were subsequently docked onto both target proteins using Maestro (Schrödinger 2020−3). The best-scoring compounds against PKG and CK2 were Ligand-9 (−7.490 kcal/mol) and Ligand-13 (−11.468 kcal/mol), respectively. These lead compounds may be useful as therapeutic targets based on an assessment of their pharmacological, toxicological, and bioactivity characteristics. Furthermore, Ligand-13’s strong reactivity and stability were demonstrated by density functional theory analysis, and these findings were confirmed by molecular dynamics simulations and binding free energy MMGBSA calculations. These results imply that Ligand-13 may be a promising antimalarial medication.
Journal Article
Milk Containing A2 β-Casein ONLY, as a Single Meal, Causes Fewer Symptoms of Lactose Intolerance than Milk Containing A1 and A2 β-Caseins in Subjects with Lactose Maldigestion and Intolerance: A Randomized, Double-Blind, Crossover Trial
Acute-feeding and multiple-day studies have demonstrated that milk containing A2 β-casein only causes fewer symptoms of lactose intolerance (LI) than milk containing both A1 and A2 β-caseins. We conducted a single-meal study to evaluate the gastrointestinal (GI) tolerance of milk containing different concentrations of A1 and A2 β-casein proteins. This was a randomized, double-blind, crossover trial in 25 LI subjects with maldigestion and an additional eight lactose maldigesters who did not meet the QLCSS criteria. Subjects received each of four types of milk (milk containing A2 β-casein protein only, Jersey milk, conventional milk, and lactose-free milk) after overnight fasting. Symptoms of GI intolerance and breath hydrogen concentrations were analyzed for 6 h after ingestion of each type of milk. In an analysis of the 25 LI subjects, total symptom score for abdominal pain was lower following consumption of milk containing A2 β-casein only, compared with conventional milk (p = 0.004). Post hoc analysis with lactose maldigesters revealed statistically significantly improved symptom scores (p = 0.04) and lower hydrogen production (p = 0.04) following consumption of milk containing A2 β-casein only compared with conventional milk. Consumption of milk containing A2 β-casein only is associated with fewer GI symptoms than consumption of conventional milk in lactose maldigesters.
Journal Article